Webb27 mars 2024 · Carboplatin-paclitaxel (CP) is standard of care (SOC) for first-line treatment of primary A/R EC; median OS is <3 yrs. Use of anti–PD-1s with chemo has improved … WebbClinical trials are a key testing ground for determining the effectiveness and safety of new treatments and drugs for cancer and other diseases. Our doctors may recommend that cancer patients enroll in cancer clinical trials if they meet specific criteria.
GSK announces phase III RUBY trial demonstrates potential of …
Webb11 nov. 2024 · by Steve Bryson, PhD November 11, 2024. Enrollment is underway for a Phase 1/2 trial evaluating the safety and efficacy of EDIT-301, an experimental gene … Webb25 okt. 2024 · We have RUBY Part 1, which is dostarlimab. We have NRG-GY018, which was plus or minus pembrolizumab. All of those have the carboplatin-paclitaxel backbone plus or minus IO. That’s different... integrated band depth
Phase III RUBY clinical trial demonstrates potential of Jemperli ...
WebbThe RUBY trial will evaluate the efficacy and safety of dostarlimab in combination with carboplatin-paclitaxel in recurrent or primary advanced EC compared with carboplatin-paclitaxel alone. Trial Design This is a global, randomised, double-blind, multicenter, placebo-controlled study. Webb11 apr. 2024 · Objective Identify resistance patterns against various antibiotics in Escherichia coli producers and non-producers of extended spectrum beta-lactamases in urinary infections in a population of the Toluca Valley, Mexico Introduction Escherichia coli is a bacterium that is part of the normal biota of the human being, but under certain … Webb11 jan. 2024 · The RUBY Trial is a single-arm, open-label, multi-center Phase 1/2 study designed to assess the safety and efficacy of EDIT-301 in people with severe sickle cell disease. Enrolled patients will receive a single administration of EDIT-301. … jocko valley baptist church